Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Total product and royalty revenues of $728 million in Q1’22 (+20% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $544 million in Q1’22 (+17% Y/Y); raising the bottom end of full year guidance to new range of $2.33 to $2.40 billion Robust uptake of Opzelura™ (ruxolitinib) cream with over 38,000